John Neis

Venture Investors LLC (Venture Investors) is a venture capital firm founded in 1984. The firm is headquartered in Madison, Wisconsin.

Mithridion, Inc. develops and manufactures biopharmaceutical products. Its drugs are used for the treatment of Alzheimer's's disease and schizophrenia. The company was founded on November 19, 2004 and is headquartered in Madison, WI.

TomoTherapy, Inc. manufactures and provides radiation treatment systems for advanced radiation therapy. It provides radiation treatment services for cancer patients with its TomoTherapy Hi·Art System, which changes the intensity of the radiation beam so that it adapts to the shape of the tumor. The firm's system focuses on killing cancer cells while sparing healthy tissue. The company was founded by Thomas Rockwell Mackie and Paul J. Reckwerdt in 1997 and is headquartered in Madison, WI.

NimbleGen Systems, Inc. Develops micro-arrays used in bio-technology. It also supplies microarray products and services. The company combines photo-deposition chemistry with digital light projection to shorten array fabrication from months to hours. NimbleGen System was founded in 1999 & is headquartered in Madison, WI.

Deltanoid Pharmaceuticals, Inc. researches and develops therapies for the treatment of human diseases. The firm's focus is to move therapies in a variety of areas, including renal disease, osteoporosis, vitamin D deficiency, and acne through the drug development process and seek partners for later stage development and commercialization. The company was founded by Margaret Clagett-Dame and Hector F. DeLuca in 1999 and is headquartered in Madison, WI.

Virent, Inc. develops and commercializes biofuel technologies. It converts soluble biomass-derived sugars into products molecularly identical to those made with petroleum, including gasoline, diesel, jet fuel, and chemicals used for plastics and fibers. The company was founded by Randy D. Cortright and James Dumesic in 2002 and is headquartered in Madison, WI.

Wisconsin Technology Council provides science and technology advisory services to the Governor and the Legislature. The company was founded in 2001 and is headquartered in Madison, WI.

Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way.